Forest Monurol single-dose therapy for uncomplicated UTI approved Dec. 19.
Executive Summary
FOREST MONUROL SINGLE-DOSE UTI THERAPY WILL BE LAUNCHED IN APRIL, following FDA's Dec. 19 approval of the drug, the company said. Forest's marketing strategy for Monurol (fosfomycin tromethamine) will emphasize its status as the first one-dose antibiotic available for uncomplicated urinary tract infections.